Boston, MA 01/10/2013 (wallstreetpr) – Nuvilex Inc (OTCMKTS:NVLX) owns Medical Marijuana Sciences as its wholly-owed subsidiary. It is important to point this out from the onset so that the rest of this article can make sense. At the moment, there is a lot which is going on in the medical marijuana industry following the legalization of marijuana in Colorado.
The general direction of most, if not all marijuana related stocks has been up since the year began. Of course, opportunistic investors have made millions of dollars shorting pot stocks. Since Nuvilex Inc (OTCMKTS:NVLX) has a hand in weed industry, it deserves a closer look to see if it offers any opportunity for investors thinking about investment in the sector.
The current investor enthusiasm that is seen in marijuana stocks will eventually fizzle out sooner or later and what will result is serious correction of the stocks. That is why a promising company in the industry is that which is developing future product for opportunities in the sector. Nuvilex Inc (OTCMKTS:NVLX) is one such company.
The company is following the winning script that has worked for many successful companies and this is about signing talented agents in the marijuana research industry. Towards this end, the company named Dr. Mark Rabe to the chairmanship of Medical Marijuana Sciences’ Science Advisory Board (SAB). Rabe is a well-known personality in the medical marijuana research.
Now Rabe is not just bringing unmatched professional reputation to the company, be he is also leading the recruitment of stellar credentials to SAB. All this is expected to culminate in the development of revolutionary cannabis-linked medication. This will therefore fulfill the general objective of Medical Marijuana Sciences in being the leader in the medication marijuana research.
Stock performance
The stock of Nuvilex Inc (OTCMKTS:NVLX) is trading upward these days following the prospects of its ongoing marijuana research and the fever in the sector due to the legalization of weed-based medication in Colorado. At the moment, the stock looks ripe for uptake due its strengths which surpass any potential weaknesses.
